Paratek Pharma buy stratec
Start price
02.03.18
/
50%
€11.28
Target price
04.03.19
€21.65
Performance (%)
-49.04%
End price
04.03.19
€5.75
Summary
This prediction ended on 04.03.19 with a price of €5.75. Massive losses of -49.04% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Paratek Pharma | - | - | - | - |
| iShares Core DAX® | -2.023% | -3.140% | 10.499% | 13.078% |
| iShares Nasdaq 100 | 4.625% | 8.753% | 34.939% | 57.906% |
| iShares Nikkei 225® | -2.088% | -0.980% | 3.292% | 2.524% |
| iShares S&P 500 | 2.398% | 4.677% | 27.998% | 49.604% |
Comments by stratec for this prediction
In the thread Paratek Pharma diskutieren
Paratek set the First new class of antibiotics in 30 years.
stratec stimmt am 02.03.2018 dem Sell-Crowdsentiment mit dem Kursziel 7.8$ nicht zu.
Antibiotic Omadacycline has broad spectrum activity and is effective in both an IV and oral form making it ideal for resistant infections, and set the First new class of antibiotics in 30 years. It has completed three successful Phase 3 clinical trials in CABP and ABSSSI and reached the highest confidence intervals ever achieved for an antibiotic. Approval expected in 2018.
(Laufzeit überschritten)